Techinvention to oversee Botswana Vaccine Institute’s new vaccine manufacturing unit

Partnership with Botswana Vaccine Institute set to enhance regional healthcare capabilities with new veterinary vaccine facility

New Delhi: Techinvention Lifecare Private Limited has been appointed by Botswana Vaccine Institute (BVI) to manage the establishment of a cutting-edge veterinary vaccine manufacturing unit at its facility in Gaborone, Botswana.
The project, slated to meet current Good Manufacturing Practices (cGMP) standards, marks a significant expansion for BVI, a key player in veterinary vaccines since the 1970s.
The scope of Techinvention Lifecare’s role includes comprehensive project management to ensure the new blending and filling block for veterinary vaccines meets stringent global standards. This initiative aims to not only increase production capacity but also enhance product quality, efficacy, and safety. Regulatory approvals are a priority, facilitating BVI’s ability to introduce more products locally and explore new markets.
The project began in 2022 and is slated for completion and activation by 2026. Syed Ahmed, CEO of Techinvention, has pledged full support to BVI in achieving this goal, underscoring the facility’s strategic importance and its critical role for the region. 
Meanwhile, Andrew Madeswi, CEO of BVI, reaffirmed their dedication to enhancing manufacturing capabilities at the state-of-the-art facility, ensuring the production of affordable, high-quality vaccines for local, regional, and international markets while adhering to cGMP standards.